We show the evolution of a case of EGFR mutant lung cancer treated with a combination of erlotinib, osimertinib, radiotherapy and a personalized neopeptide vaccine targeting somatic mutations, including EGFR exon 19 deletion.

EGFR-Mutant NSCLC Management in Cantonese - IASLC / cancer, EGFR-mutant, IASLC, International Association for the Study of Lung Cancer, Molly Li, OncoDaily,

Signal Transduction and Targeted Therapy - CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer

Third-generation EGFR tyrosine-kinase inhibitors (TKIs) are the standard-of-care first-line treatment for patients with advanced-stage EGFR-mutant NSCLC and their efficacy is being investigated in ear...

Stephen V Liu: How do we overcome resistance to osimertinib in EGFR mutant NSCLC? / cancer, OncoDaily, Oncology, Rachel E. Sanborn, Stephen V Liu, Yasushi Goto

Osimertinib resistance represents a significant challenge in the management of EGFR-mutant NSCLC. MET alteration is a common resistance mechanism and previous work has established that combination EGFR/MET inhibition may represent a viable treatment strategy in this population. There are emerging data suggesting that a combination of capmatinib and osimertinib (cap/osi) will be effective in this setting although prospective data is limited.

Therapeutic strategies after progression on third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) remain suboptimal in EGFR-mutant non-small cell lung cancer (NSCLC). We investigated whether co...

Read the full paper: Targeting ABCA3 impedes tumor progression and EGFR-TKI resistance in EGFR-mutant LUAD

ArriVent’s Firmonertinib Fails in First-Line EGFR-Mutant NSCLC Trial

Targeting the Ras pathway effector SOS1 sustains the sensitivity of lung cancer cells to EGFR inhibition.

Background Epidermal growth factor receptor (EGFR) T790M mutation often occurs during long durational erlotinib treatment of non-small cell lung cancer (NSCLC) patients, leading to drug resistance and...

Racura Oncology has received approval to escalate the dosage of its drug RC220 in the HARNESS-1 trial, aimed at treating EGFR-mutant lung cancer, marking a significant step in cancer research.

EGFR-mutant NSCLC is associated with low mutation burden and low levels of PD-L1 expression. We conducted a phase 2 trial to determine the efficacy of durvalumab, tremelimumab and platinum-pemetrexed ...

PIK3CA mutation is frequently concurrent with known oncogenic drivers such as EGFR mutation in lung cancer, raising an interesting question about its real function. Cachexia is a systemic disease invo...

Updates from several clinical trials of the EGFR tyrosine kinase inhibitor osimertinib across stages and settings of EGFR-mutated non–small cell lung cancer (NSCLC) were presented at the European Lun....

Aakash Desai: Phase 2 Silevertinib Results in Non-Classical EGFR-Mutant NSCLC / Aakash Desai, ASCO26, Black Diamond Therapeutics, cancer, Lung cancer, NSCLC,

Pathologic transformation in KrasG12D-mutant alveolar type II cells initiates a tumour-permissive niche by orchestrating epithelial, stromal and immune reprogramming through amphiregulin–EGFR signalli...

Phase II study shows promise in setting of third-generation EGFR TKI resistance

FDA approves datopotamab deruxtecan-dlnk for pretreated EGFR-mutant NSCLC after EGFR-TKI + plat therapy; 45 % ORR, 6.5month DOR.

We show the evolution of a case of EGFR mutant lung cancer treated with a combination of erlotinib, osimertinib, radiotherapy and a personalized neopeptide vaccine targeting somatic mutations, includi...

Epigenetic changes, such as LSD1 dysregulation, contribute to acquired resistance in EGFR mutant NSCLCs and reduce the effectiveness of current therapeutics. To address the challenges, we herein repor...